This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Karyopharm Therapeutics Inc. [KPTI] To Ring The NASDAQ Stock Market Closing Bell

ADVISORY, Feb. 5, 2014 (GLOBE NEWSWIRE) --

What:

Karyopharm Therapeutics Inc. [KPTI], a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, will visit the NASDAQ MarketSite in Times Square.

  • Karyopharm completed a successful IPO in November 2013, which raised gross proceeds of over $125M.
  • Karyopharm presented data from the Phase 1 trial of its lead drug candidate, Selinexor (KPT-330), in patients with heavily pretreated hematologic malignancies at the 2013 American Society of Hematology Annual Meeting showing preliminary evidence of broad anti-cancer activity as an oral, single agent therapy.
  • Data were also presented at the American Society of Clinical Oncology 2014 Gastrointestinal Cancers Symposium from the Phase 1 study of Selinexor showing preliminary evidence of antitumor activity in metastatic colorectal cancer patients whose tumors were progressing at the start of the study.
  • Karyopharm expects to initiate registration-directed trials of Selinexor in the first half of 2014.

Sharon Shacham, Ph.D., M.B.A., Founder, President and Chief Scientific Officer and Michael Kauffman, M.D., Ph.D., Chief Executive Officer, will ring the Closing Bell. Drs. Shacham and Kauffman will be joined by the entire Karyopharm team to celebrate the occasion.

Where:

NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio

When:

Thursday, February 6, 2014 – 3:45 p.m. to 4:00 p.m. ET

Contact : Beth DelGiacco (212) 362-1200 beth@sternir.com

NASDAQ MarketSite: Christine Barna (646) 441-5310 Christine.Barna@nasdaqomx.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.

For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/

Webcast:

A LiveStream of the NASDAQ Closing Bell will be available at: https://new.livestream.com/nasdaq/live  Or http://www.nasdaq.com/about/marketsitetowervideo.asx.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.                   

About Karyopharm Therapeutics Inc. [KPTI]:

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by blocking XPO1, preventing the export of various proteins out of the nucleus. SINE compounds have shown biological activity in models of cancer, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Natick, Massachusetts.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs